RT Journal Article
SR Electronic
T1 Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.20.21263875
DO 10.1101/2021.09.20.21263875
A1 Danuta M Skowronski
A1 Solmaz Setayeshgar
A1 Macy Zou
A1 Natalie Prystajecky
A1 John R Tyson
A1 Hind Sbihi
A1 Chris D Fjell
A1 Eleni Galanis
A1 Monika Naus
A1 David M Patrick
A1 Shiraz El Adam
A1 May Ahmed
A1 Shinhye Kim
A1 Bonnie Henry
A1 Linda M N Hoang
A1 Manish Sadarangani
A1 Agatha N Jassem
A1 Mel Krajden
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263875.abstract
AB Introduction In randomized controlled trials, single-dose efficacy against SARS-CoV-2 illness exceeded 90% for mRNA vaccines (BNT162b2 and mRNA-1273), and 75% for ChAdOx1. In British Columbia (BC), Canada second doses were deferred up to 16 weeks and ChAdOx1 was only initially recommended for adults 55 years of age and older. We compared single-dose vaccine effectiveness (VE) during the spring 2021 wave in BC when Alpha and Gamma variants of concern (VOC) predominated.Methods VE was estimated against infection and hospitalization by test-negative design: cases were RT-PCR test-positive for SARS-CoV-2 and controls were test-negative. Adults 50-69 years old with specimen collection between April 4 and May 22 (weeks 14-20) were included. Variant-specific VE was estimated between weeks 17-20 when genetic characterization of all case viruses was performed, primarily through whole genome sequencing.Results VE analyses included 7,116 (10%) cases and 60,958 controls. Three-quarters of vaccinated participants received mRNA vaccine (60% BNT162b2, 15% mRNA-1273) and 25% received ChAdOx1. Half of genetically characterized viruses were Alpha, with 38% Gamma, 4% Delta and 8% non-VOCs. Single-dose VE against any infection was 75% (95%CI: 72-78) for BNT162b2, 82% (95%CI: 76-87) for mRNA-1273 and 61% (95%CI: 54-66) for ChAdOx1. VE against hospitalization was 83% (95%CI: 76-89), 85% (95%CI: 63-94) and 96% (95%CI: 86-99), respectively. VE against Alpha vs. Gamma infections did not differ among mRNA (78%;95%CI: 73-82 and 80%;95%CI: 74-85) or ChAdOx1 (66%;95%CI: 57-74 and 60%;95%CI: 48-69) recipients.Conclusions A single dose of mRNA vaccine reduced the SARS-CoV-2 infection risk by at least 75%, including infections due to early VOC. Although effectiveness of a single dose of ChAdOx1 was lower at 60% against infection, just one dose of any vaccine reduced the hospitalization risk by more than 80%. In the context of constrained vaccine supplies, these findings have implications for global vaccine deployment to reduce the overall burden of infections and hospitalizations due to SARS-CoV-2.Competing Interest StatementDMS is Principal or co-Investigator on grants from the Michael Smith Foundation for Health Research, the Public Health Agency of Canada, and the Canadian Institutes of Health Research paid to her institution and unrelated to the current work. MK received grants/contracts paid to his institution from Roche, Hologic and Siemens, unrelated to this work. MS has been an investigator on projects, unrelated to the current work, funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. Other authors have no conflicts of interest to disclose.Clinical TrialNot applicableFunding StatementNo external funding was provided for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data linkages and analyses were authorized by the Provincial Health Officer under the Public Health Act and exempt from research ethics board review by the University of British Columbia Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing that complies with relevant legislation to protect privacy and confidentiality will be considered upon request.